The steroidal hormones testosterone and dihydrotestosterone are the major endogenous androgens that cause nuclear translocation and subsequent activation of androgen receptor (AR).^[@ref1]^ In prostate cancer, AR shows a higher nuclear concentration in the presence of androgens,^[@ref2],[@ref3]^ and androgen-deprivation therapy (ADT) is one of the primary treatments.^[@ref4]^ Unfortunately, even with ADT, almost all patients eventually progress to the stage of castration-resistant prostate cancer (CRPC, formerly known as hormone-refractory prostate cancer), a fatal condition that makes prostate cancer the second most deadly cancer type in men in the U.S.^[@ref5]^ Despite a high survival rate with early detection and treatment with surgery or radiation, prostate cancer is responsible for the death of 30,000 patients each year in the U.S.^[@ref5],[@ref6]^

CRPC is postulated to arise through either adaption or selection of cancer cells in a low androgen environment^[@ref7]^ as a result of the initial ADT.^[@ref4],[@ref8]^ In the laboratory setting, studies of overexpression^[@ref9]^ and knockdown^[@ref10]^ of AR have shown that this receptor plays a key role in the progression of CRPC.^[@ref11],[@ref12]^ Enzalutamide (MDV3100) and bicalutamide are AR antagonists that are currently used as treatments for CRPC and can extend the lifespan of patients for 3--5 months ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Enzalutamide, in particular, attenuates nuclear translocation of AR but does not seem to reduce nuclear levels of AR in prostate cancer cells.^[@ref13]^ Since these therapeutics are only partially effective, there is a definite need for new regimens that extend life expectation beyond several months.^[@ref14]^ Unfortunately, there are no known therapies that decisively inhibit nuclear localized AR in CRPC cells.^[@ref15]−[@ref22]^ Herein, we investigate a novel series of small molecules identified by their ability to reduce the nuclear level of AR and, subsequently, AR activity.

![Structures of clinically used AR antagonists enzalutamide and bicalutamide.](ml-2016-00186c_0002){#fig1}

Prior to the onset of our medicinal chemistry efforts, a high-throughput screening (HTS) campaign for antagonists of AR nuclear localization identified compounds **1** and **2** that also reduced levels of prostate-specific antigen (PSA), a key marker for CRPC, in a PSA luciferase reporter assay performed in CRPC cell lines ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}).^[@ref23]^ Both HTS hits demonstrated low micromolar potency with little to no cytotoxicity or activity in AR negative cell lines. Close structural analogues of 3-phenyl-6,7-dihydro-5-pyrrolo\[1,2-*a*\]imidazole (**2**) were previously found to have antifungal effects, which raised off-target concerns.^[@ref24]^ In contrast, 2-((isoxazol-4-ylmethyl)thio)-1-(4-phenylpiperazin-1-yl)ethanone (**1**) had not yet been biologically annotated, and this structural novelty led us to prioritize this scaffold over **2**. In an effort to determine a structure--activity relationship and identify more potent antagonists of CRPC, we designed and synthesized analogues of **1** in a series of structural modifications of subunits 1--5 ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}).

![HTS hits that reduced PSA levels in a luciferase assay in CRPC cell lines.^[@ref23]^](ml-2016-00186c_0003){#fig2}

![Zones of planned structural modifications of **1**.](ml-2016-00186c_0004){#fig3}

Our goal was to probe five key moieties in compound **1**: the benzene substitution pattern (zone 1), modifications at the piperazine (zone 2), carbonyl replacements (zone 3), a sulfur-atom exchange in the 3-atom linker and the use of less flexible linkers (zone 4), and variations of the 3,5-dimethylisoxazole (3,5-DMI) ring (zone 5) ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}).

In the synthesis of zone 1--3 analogues, we used the amide bond as the lynchpin disconnection. Compounds **5a**--**h** were synthesized directly from commercially available carboxylic acid **3a** and *N*-arylated piperazines **4a**--**h** under amide coupling conditions with T3P ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"} and [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}).^[@ref25]^ We also examined the diamine linker in zone 2 in more detail through the synthesis of analogues **5i**--**5m**. For these target molecules, the requisite diamines **4i**--**m** were prepared by a Buchwald--Hartwig cross-coupling of mono-Boc-protected diamines with bromoarenes.^[@ref26],[@ref27]^ Reduction of amide **5b** with lithium aluminum hydride led to diamine **6**. For an initial set of zone 4 analogues, thioether **5b** was also oxidized to sulfoxide **12** and sulfone **13** in good yields with sodium periodate and *m*-chloroperbenzoate, respectively ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![Synthesis of DMI-Containing Analogues **5**, **6**, **12**, and **13**\
Reagents and conditions: (a) T3P, Et~3~N, CH~2~Cl~2~, rt, overnight, 52--98%; (b) LiAlH~4~, dry THF, 0 °C, 1 h, 42%; (c) NaIO~4~, MeOH, H~2~O, rt, 15 h, 68%; (d) *m*-CPBA, CH~2~Cl~2~, rt, 15 h, 44%.](ml-2016-00186c_0006){#sch1}

###### Structures of Amine Building Blocks **4** and Analogues **5**, **7**--**11**, and **16** ([Schemes [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"} and [2](#sch2){ref-type="scheme"})

![](ml-2016-00186c_0010){#fx1}

Additional zone 4 and zone 5 analogues with a phenyl group in place of the isoxazole ring were obtained from carboxylic acids **3b**--**3g** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"} and [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Coupling to piperazine **4b** provided amides **7**--**11** and **16** in high yields. Alkynyl amide **10** was further hydrogenated to *cis*-alkene **14** using a Lindlar catalyst. The *cis*-cyclopropane **15** was prepared by a Simmons--Smith cyclopropanation of *cis*-alkene **14**,^[@ref28]^ whereas the *trans*-cyclopropane **16** was obtained by coupling of commercially available *trans*-2-phenylcyclopropanecarboxylic acid **3g** with piperazine **4b**.

![Synthesis of Piperazines **7**--**11** and **14**--**16**\
Reagents and conditions: (a) T3P, Et~3~N, CH~2~Cl~2~, rt, overnight, 62--96%; (b) Lindlar's catalyst, quinoline, H~2~, EtOAc, quant.; (c) CrCl~2~, CH~2~ICl, THF, reflux, overnight, 57%.](ml-2016-00186c_0007){#sch2}

Further modifications in zones 3--4 were accomplished by acylation of piperazine **4b** with either 2-chloroacetyl chloride or chloromethanesulfonyl chloride to form the corresponding amide **17a** or sulfonamide **17b** in good yields ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). S~N~2 reaction of **17a** and **17b** led to ether **18a**, amine **18b**, and thioether **18c**. Starting with carboxylic acid **3a**, urea **20a** and carbamate **20b** were obtained in moderate yields via a Curtius rearrangement and addition of the intermediate isocyanate **19** to amine **4b** and alcohol **4n**, respectively ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}).^[@ref29]^

![Alkylation of **17a** and **17b** To Give Analogues **18a**--**18c** and Conversion of Isocyanate **19** To Give Thioethers **20a/b**\
Reagents and conditions: (a) 2-chloroacetyl chloride, Et~3~N, CH~2~Cl~2~, rt, overnight, 99%; (b) chloromethanesulfonyl chloride, Et~3~N, CH~2~Cl~2~, rt, overnight, 85%; (c) NaH, THF, rt, 1--2 d, 4--99%; (d) DPPA, Et~3~N, toluene, reflux, overnight, 17--65%.](ml-2016-00186c_0008){#sch3}

A bridged bicyclic ring was introduced to add a strong conformational constraint in zone 2 ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). Boc-protection of nortropinone hydrochloride **21** followed by enolization with NaHMDS and trapping of the enolate with *N*-phenyltriflimide provided vinyl triflate **22** in good yield. A Suzuki coupling was used to install the *o*-tolyl group, and the styrene double bond was reduced with Pd/C to afford **23** as a mixture of diastereomers. Without separation, this mixture was deprotected and acylated with α-chloroacetyl chloride. Finally, the chloride was displaced using thiol **25** and sodium hydride to afford the thioether. Diastereomers **26a** and **26b** were separated by chromatography on SiO~2~ to afford both analogues in modest yields.

![Synthesis of Bridged Analogues **26a** and **26b**\
Reagents and conditions: (a) Boc~2~O, DMAP, CH~2~Cl~2~, rt, overnight, 78%; (b) NaHMDS, PhNTf~2~, THF, −78 °C to rt, 4 h, 78%; (c) Pd(PPh~3~)~4~, LiCl, Na~2~CO~3~, (2-Me)PhB(OH)~2~, DME, H~2~O, 60 °C, 3 h, 78%; (d) H~2~, Pd/C, EtOH, rt, 14 h, 90%; (e) TFA, CH~2~Cl~2~, rt, 16 h, quant.; (f) 2-chloroacetyl chloride, Et~3~N, THF, rt, 22 h, 79%; (g) **25**, NaH, THF, rt, 1 d, 30%.](ml-2016-00186c_0009){#sch4}

The biological activity of analogs **5**--**16**, **18**, **20**, and **26** was determined and compared to HTS hit **1** (EC~50~ 7.3 μM) and enzalutamide (EC~50~ 1.1 μM) using the Dual-Glo luciferase system (Promega, WI, USA) in the presence of 1 nM synthetic androgen R1881 in C4-2-PSA-rl cells, which were generated by stable cotransfection of C4-2 cells with a PSA promoter driven luciferase reporter vector (pPSA6.1) and a Renilla luciferase reporter vector as a control. Relative luciferase activity was calculated as the quotient of androgen-induced PSA-firefly/Renilla luciferase activity. Since PSA promoter activity correlates to AR transcriptional activity, inhibition of AR will result in decreased PSA-luciferase activity. EC~50~ values were calculated using graphpad prism, and data represent the mean and SD of 2--6 independent experiments ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). To verify that these compounds did not have undesirable electrophilic properties, their stability was tested in the presence of thiols. Neither thiophenol in CDCl~3~ nor 2-mercaptoethanol in PBS resulted in any trapping products by ^1^H NMR and LCMS analysis.

###### In Vitro Activity of Analogues in the PSA Luciferase Assay in C4-2-PSA-rl Cells

  entry   compd    EC~50~ (μM)                                  entry   compd                EC~50~ (μM)
  ------- -------- -------------------------------------------- ------- -------------------- ---------------------------------------------
  1       **1**    7.3 ± 2.5[c](#t2fn4){ref-type="table-fn"}    19      **10**               20.3 ± 11.6[a](#t2fn2){ref-type="table-fn"}
  2       **5a**   \>25[a](#t2fn2){ref-type="table-fn"}         20      **11**               \>25[a](#t2fn2){ref-type="table-fn"}
  3       **5b**   14.5 ± 3.2[b](#t2fn3){ref-type="table-fn"}   21      **12**               \>25[b](#t2fn3){ref-type="table-fn"}
  4       **5c**   \>25[a](#t2fn2){ref-type="table-fn"}         22      **13**               16.1 ± 3.3[b](#t2fn3){ref-type="table-fn"}
  5       **5d**   \>25[a](#t2fn2){ref-type="table-fn"}         23      **14**               12.7 ± 0.8[a](#t2fn2){ref-type="table-fn"}
  6       **5e**   12.0 ± 1.6[b](#t2fn3){ref-type="table-fn"}   24      **15**               2.9 ± 1.0[b](#t2fn3){ref-type="table-fn"}
  7       **5f**   12.6 ± 7.7[b](#t2fn3){ref-type="table-fn"}   25      **16**               \>25[b](#t2fn3){ref-type="table-fn"}
  8       **5g**   11.1 ± 5.3[b](#t2fn3){ref-type="table-fn"}   26      **18a**              \>25[b](#t2fn3){ref-type="table-fn"}
  9       **5h**   \>25[a](#t2fn2){ref-type="table-fn"}         27      **18b**              \>25[b](#t2fn3){ref-type="table-fn"}
  10      **5i**   18.4 ± 9.2[b](#t2fn3){ref-type="table-fn"}   28      **18c**              7.2 ± 2.7[c](#t2fn4){ref-type="table-fn"}
  11      **5j**   11.1 ± 3.3[a](#t2fn2){ref-type="table-fn"}   29      **20a**              \>25[a](#t2fn2){ref-type="table-fn"}
  12      **5k**   3.1 ± 1.1[a](#t2fn2){ref-type="table-fn"}    30      **20b**              \>25[c](#t2fn4){ref-type="table-fn"}
  13      **5l**   14.7 ± 4.4[a](#t2fn2){ref-type="table-fn"}   31      **26a**              7.7 ± 1.6[b](#t2fn3){ref-type="table-fn"}
  14      **5m**   16.6 ± 4.8[b](#t2fn3){ref-type="table-fn"}   32      **26b**              7.9 ± 2.8[a](#t2fn2){ref-type="table-fn"}
  15      **6**    10.8 ± 5.7[b](#t2fn3){ref-type="table-fn"}   33      enzalutamide         1.1 ± 0.5[e](#t2fn6){ref-type="table-fn"}
  16      **7**    13.7 ± 0.8[b](#t2fn3){ref-type="table-fn"}   34      **27**               2.7 ± 1.1[d](#t2fn5){ref-type="table-fn"}
  17      **8**    14.4 ± 3.7[b](#t2fn3){ref-type="table-fn"}   35      (1*S,*2*R*)-**27**   1.7 + 0.2[a](#t2fn2){ref-type="table-fn"}
  18      **9**    \>25[a](#t2fn2){ref-type="table-fn"}         36      (1*R,*2*S*)-**27**   15.2 ± 3.3[a](#t2fn2){ref-type="table-fn"}

Assay repeats. *n* = 2.

*n* = 3.

*n* = 4.

*n* = 5.

*n* = 6. For assay description and complete structural information, please see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.6b00186/suppl_file/ml6b00186_si_001.pdf) and Table S1.

Simple modifications of the substituents on the benzene ring in zone 1 revealed that methyl groups in the 3- and 4-positions (**5c**, **5d**) led to loss of activity, while the 2-methyl analogue **5b** (EC~50~ 14.5 μM) retained about half of the activity of the 2,3-dimethylated **1** ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). Removal of the 2-methyl group in **5a** deleted activity. In agreement with this trend in zone 1, the bulky 1-naphthyl substituent (**5g**) recovered activity (EC~50~ 11.1 μM). Analogues with electron-withdrawing substituents at the benzene 2-position (2-NC, **5e**, and 2-F, **5f**) also maintained or slightly increased activity (EC~50~ 12--13 μM); however, the electron-donating 2-methoxy substituted **5h** was not tolerated and resulted in a complete loss of activity, possibly due to an increase in the p*K*~a~ of the aniline and/or an unfavorable increase in the π-electron density of the aromatic ring.^[@ref30]^ To potentially reduce the expected rapid metabolism of benzylic methyl groups by cytochrome P450 enzymes,^[@ref31]^ we selected the minimally required substitution in zone 1, e.g., the 2-methyl group, for further structure--activity relationship (SAR) investigations.

The piperazine core (zone 2) was queried through substitutions with flexible as well as constrained acyclic and cyclic diamines. The flexible *N*,*N*′-dimethylethylenediamine linker in **5i** (EC~50~ 18.4 μM) and the 7-membered diazepane **5j** (EC~50~ 11.1 μM) both dropped off in activity. The dimethylated piperazines **5l** and **5m** (EC~50~ 15--17 μM) were also less active than the initial hit. In contrast, the conformationally more highly constraint 2,6-dimethylpiperazine **5k** was more active with an EC~50~ of 3.1 μM. Installment of an ethylene bridge and a carbon-linked (2-Me)Ph group decreased activity again since both diastereomers of the bicyclo\[3.2.1\] ring systems **26a** and **26b** showed an EC~50~ of 8 μM.

Reduction of amide **5b** to amine **6** resulted in a 1.3-fold increase in activity to an EC~50~ of 10.8 μM. Sulfonamide **18c** (EC~50~ 7.2 μM) was as active as the initial hit **1**, but urea **20a** and carbamate **20b** were inactive.

The replacement of the thioether linkage in zone 2 with an ether group abolished activity in **18a**. Substituting the thioether with the *N*-methylated amine in **18b** also abolished activity. In contrast, in an analogous system with a phenyl group in place of the isoxazole, both thioether **7** as well as the all-carbon chain containing **8** showed decreased yet consistent activity (EC~50~ ≈ 14 μM).

In order to verify that the biological effect in the thioether series was not a result of *S*-oxidation in the cellular assay, common products of thioether oxidation, i.e., sulfoxide **12** and sulfone **13**, were tested. While sulfone **13** retained some activity (EC~50~ 16.1 μM), sulfoxide **12** was inactive. Shortening the three-atom chain to afford the two-atom thioether-linked **9** also abolished activity. The rigidified alkyne **10** and the corresponding (*E*)-alkene **11** and its cyclopropane isostere **16** were also found to be essentially inactive. In contrast, we were pleasantly surprised to find that the (*Z*)-alkene **14** showed an EC~50~ of 12.7 μM and that the corresponding *cis*-fused cyclopropane isostere^[@ref32]^**15** was even more potent than analogue **1**, showing an EC~50~ of 2.9 μM ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). More significantly, chiral resolution of the bis-halogenated cyclopropane **27** (EC~50~ 2.7 μM, entry 34) provided a more potent enantiomer (1*S,*2*R*)-**27** (EC~50~ 1.7 μM, entry 35) and the ca. 10-fold less potent (1*R,*2*S*)-**27** (EC~50~ 15.2 μM, entry 36), and supporting specific contact of this scaffold at a still to be defined AR binding site ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}).

![More potent enantiomer of cyclopropane **27**.](ml-2016-00186c_0005){#fig4}

In summary, 35 analogues were synthesized, and the resulting SAR evaluated 5 zones of modification in the starting hit, compound **1**. We discovered several attributes that proved essential for activity. Zone 1 modifications showed that the *ortho*-substituent on the phenyl ring was important for activity. In zone 2, the sterically encumbered 2,6-dimethylpiperazine proved superior to flexible, unsubstituted, and bridged analogues. In zone 3, a carbonyl group was not required, and a sulfonamide and even the reduced amine were well tolerated. In zone 4, thioether oxidation reduced activity, and only the *cis*-cyclopropane significantly improved the EC~50~. Limited substitutions were performed in zone 5, but in general, analogues with a phenyl group were equipotent with their 3,5-dimethylisoxazole congeners (see, for example, **7** vs **5b**). The *cis*-cyclopropane (1*S,*2*R*)-**27** was found to be substantially equipotent to the commercial AR antagonist, enzalutamide. Compound (1*S,*2*R*)-**27** is of particular interest in comparison to **1** due to the isosteric replacement of the thioether linker with the metabolically more stable cyclopropane, a reduction of the topological polar surface area (TPSA) from 49.6 to 23.6 Å^2^, a reduction of the number of rotatable bonds from 3 to 2, and an improvement in the drug-likeness score from 6.3 to 8.0.^[@ref33]^ Further modifications of lead structure **27** based on these SAR results as well as *in vivo* tumor xenograft data will be reported in due course.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsmedchemlett.6b00186](http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.6b00186).Methods for all assays, cell cultures, treatment conditions, and compound synthesis ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.6b00186/suppl_file/ml6b00186_si_001.pdf))
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